SAN CARLOS, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its second quarter 2017 financial and operating results after the close of the U.S. financial markets on Tuesday, August 1, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 5:00 p.m. ET.
In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 47307932. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: http://edge.media-server.com/m/p/so22t2sr.
A replay of the call will be available one hour after the end of the call on August 1, 2017 until 8:00 p.m. ET on August 31, 2017. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 47307932. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with refractory metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and cervical cancer. For more information, please visit http://www.iovance.com.
Investor Contact: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 email@example.com Media Contact: Media Relations Contact: Evan Smith/Kotaro Yoshida FTI Consulting 212-850-5622/212-850-5690 firstname.lastname@example.org email@example.com
Source:Iovance Biotherapeutics, Inc.